Archive for January, 2004
FDA big factor behind high US drug costs
FDA big factor behind high US drug costs
The U.S. Food and Drug Administration, with its costly and time-consuming drug approval process, is a big reason Americans pay far more for medicine than consumers in the rest of the world, U.S. Nobel laureate Milton Friedman said Tuesday.
FDA Begins Push to End Drug Imports
FDA Begins Push to End Drug Imports
A second ‘blitz’ inspection by federal drug and customs officials of medicines imported from Canada has found that nearly all of the almost 2,000 packages opened contained foreign versions of American pharmaceuticals that officials said might not be safe.
What To Expect From A Venture Capitalist
What To Expect From A Venture Capitalist
The more important question is, ‘What can I expect out of a good venture capitalist?’ The answer to this is: five hours per month of mindshare during which he opens doors for you with prospective customers and partners and interviews candidates for high-level positions at your company.
Is ImClone Out of the Woods?
Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth
What’s in a Drug Name?
What’s in a Drug Name?
Did you ever wonder at the bizarre brand names born by your favorite medicines? If so, you’ve probably guessed brand-name rule No. 1: They don’t actually mean anything.
Rise in biotech lawsuits
Rise in biotech lawsuits
Biotech companies were served with 17 percent of all U.S. shareholder suits last year, according to PricewaterhouseCoopers’ Securities Litigation Study of 2003.
By contrast, biotech’s estimated 350 public companies make up only 2 percent of the approximately 17,000 firms publicly traded in the United States.
